CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 532 enrolled
Drug / intervention
Nerinetide (NA-1) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02315443
NCT02315443Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous NA-1 Initiated by Paramedics in the Field for Acute Cerebral Ischemia Within Three Hours of Symptom Onset

NoNO Inc.·interventional·Posted Dec 11, 2014·Updated May 12, 2023

In Brief

A Phase 3 clinical trial evaluating Nerinetide (NA-1) and Placebo for Acute Cerebral Ischemia. Completed, enrolled 532 participants across 4 sites.

Detailed Summary

The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Cerebral Ischemia
CountriesCanada
CollaboratorsBrain Canada, Djavad Mowafaghian Centre for Brain Health, Canadian Stroke Network, University of Calgary, University of Toronto, University of British Columbia, Genome British Columbia

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 11, 2014
Enrollment StartMar 26, 2015
Primary CompletionMar 27, 2023
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 11.6 years ago

Interventions

Nerinetide (NA-1)drug

Placebodrug